Therefore, pharmacological inhibition of MEK can have effects on both tumor cells and immune cells that together may modulate tumor immunity, particularly when MEK inhibitions are combined with systemic immunotherapies such as inhibitors of the PD-1/PD-L1 axis. The gene discussed is MAP2K7; the disease is neoplasm.